Early Statin Use and the Progression of Alzheimer Disease: A Total Population-Based Case-Control Study
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
The protective effect of statin on Alzheimer disease (AD) is still controversial, probably due to the debate about when to start the use of statin and the lack of any large-scale randomized evidence that actually supports the hypothesis. The purpose of this study was to examine the protective effect of early statin use on mild-to-moderate AD in the total Taiwanese population.This was a total population-based case-control study, using the total population of Taiwanese citizens seen in general medical practice; therefore, the findings can be applied to the general population. The study patients were those with newly diagnosed dementia (ICD-9 290.x) and prescribed any acetylcholinesterase inhibitors (AChEI) from the Taiwan National Health Insurance dataset in 1997 to 2008. The newly diagnosed eligible mild-to-moderate AD patients were traced from the dates of their index dates, which was defined as the first day to receive any AChEI treatment, back to 1 year (exposure period) to categorize them into AD with early statin use and without early statin use. Early statin use was defined as patients using statin before AChEI treatment. Alzheimer disease patients with early statin use were those receiving any statin treatment during the exposure period. Then, we used propensity-score-matched strategy to match these 2 groups as 1:1. The matched study patients were followed-up from their index dates. The primary outcome was the discontinuation of AChEI treatment, indicating AD progression.There were 719 mild-to-moderate AD-paired patients with early statin use and without early statin use for analyses. Alzheimer disease progression was statistically lower in AD patients with early statin use than those without (P = 0.00054). After adjusting for other covariates, mild-to-moderate AD patients with early stain use exhibited a 0.85-risk (95% CI = 0.76-0.95, P = 0.0066) to have AD progression than those without.Early statin use was significantly associated with a reduction in AD progression in mild-to-moderate AD patients. The future randomized trial studies can confirm our findings.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neurovascular regulation in the normal brain and in Alzheimer's disease
Iadecola, C. (2004) · Nature Reviews Neuroscience · doi:10.1038/nrn1387 · Cited by 2,213
Cerebral hypoperfusion and clinical onset of dementia: the Rotterdam Study
Ruitenberg, A., den Heijer, T., Bakker, S. L. M., van Swieten, J. C., Koudstaal, P. J., Hofman, A., & Breteler, M. M. B. (2005) · Annals of Neurology · doi:10.1002/ana.20493 · Cited by 733
Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe
Feldman, H. H., Doody, R. S., Kivipelto, M., Sparks, D. L., Waters, D. D., Jones, R. W., Schwam, E., Schindler, R., Hey-Hadavi, J., DeMicco, D. A., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181d6476a · Cited by 438
Haag, M. D. M., Hofman, A., Koudstaal, P. J., Stricker, B. H. C., & Breteler, M. M. B. (2009) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2008.150433 · Cited by 393
Kaesemeyer, W. H., Caldwell, R. B., Huang, J., & Caldwell, R. W. (1999) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(98)00514-2 · Cited by 343 · cited 1×
“reduce endothelin-1, leading to vasodilatation and increase in cerebral perfusion.(6,17) In the studies of in vitro or in vivo, statin was proposed to have some neuroprotective effects through the”
BackgroundAn application of propensity score matching using claims data
Seeger, J. D., Williams, P. L., & Walker, A. M. (2005) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1062 · Cited by 218
Rusanen, M., Kivipelto, M., Levälahti, E., Laatikainen, T., Tuomilehto, J., Soininen, H., & Ngandu, T. (2014) · Journal of Alzheimer's Disease · doi:10.3233/jad-132363 · Cited by 177
More multiarm randomised trials of superiority are needed
Parmar, M. K. B., Carpenter, J., & Sydes, M. R. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61122-3 · Cited by 127
Cited by
Alzheimer’s disease: risk factors and potentially protective measures
Silva, M. V. F., Loures, C. D. M. G., Alves, L. C. V., de Souza, L. C., Borges, K. B. G., & Carvalho, M. D. G. (2019) · Journal of Biomedical Science · doi:10.1186/s12929-019-0524-y · Cited by 937
Considering sex and gender in Alzheimer disease and other dementias
Podcasy, J. L., & Epperson, C. N. (2016) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2016.18.4/cepperson · Cited by 707
Lipids and Alzheimer’s Disease
Kao, Y.-C., Ho, P.-C., Tu, Y.-K., Jou, I.-M., & Tsai, K.-J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041505 · Cited by 485
The Mechanisms of Action of Curcumin in Alzheimer’s Disease
Tang, M., & Taghibiglou, C. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-170188 · Cited by 304
Cholesterol and Alzheimer’s Disease; From Risk Genes to Pathological Effects
Feringa, F. M., & van der Kant, R. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.690372 · Cited by 226
Metadata
- Authors
- Lin, F.-C., Chuang, Y.-S., Hsieh, H.-M., Lee, T.-C., Chiu, K.-F., Liu, C.-K., & Wu, M.-T.
- Venue
- Medicine
- Published
- 2015-11
- Volume
- 94
- Issue
- 47
- Pages
- e2143
- ISSN
- 0025-7974 (ISSN-L)
- OpenAlex
- W2312632607
- Cited by
- 90
- References
- 8
- FWCI
- 4.58
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Early Statin Use and the Progression of Alzheimer Disease: A Total Population-Based Case-Control Study. https://app.cochat.ai/papers/10.1097/md.0000000000002143
- The paper
- Lin, F.-C., Chuang, Y.-S., Hsieh, H.-M., Lee, T.-C., Chiu, K.-F., Liu, C.-K., & Wu, M.-T. (2015). Early Statin Use and the Progression of Alzheimer Disease: A Total Population-Based Case-Control Study. Medicine. https://doi.org/10.1097/md.0000000000002143
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.